

Press Release

PAT up by 11%

(3rd Quarter FY 2025 Consolidated Results)

Mumbai, 30th January, 2025: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company today reported its excellent performance for 3rd quarter and nine months ended 31st December 2024.

Q3 FY 2025 performance highlights (compared to Q3 FY 2024):

- Revenue from operations at Rs. 1,146 cr. against Rs. 1,105 cr.; up 4%.
- EBITDA at Rs. 321 cr. against Rs. 314 cr.; up 2%; EBITDA at 28%.
- Profit after tax at Rs. 233 cr. against Rs. 210 cr.; up 11%; PAT at 20%.

9M FY 2025 performance highlights (compared to 9M FY 2024):

- Revenue from operations at Rs. 3,478 cr. against Rs. 3,155 cr.; up 10%.
- EBITDA at Rs. 962 cr. against Rs. 894 cr.; up 8%; EBITDA at 28%.
- Profit after tax at Rs. 695 cr. against Rs. 613 cr.; up 13%; PAT at 20%.
- Cashflow from operations (CFO) was Rs. 985 cr., EBITDA to CFO conversion of 102%.
- Free cashflow (FCF) was Rs. 675 cr., FCF to PAT conversion of 97%.
- ROCE stood at a healthy level of 35% and RONW at 26%.

Branded Generic Business:

India	<p>Q3 FY 2025, Sale was Rs. 345 cr. (Rs. 308 cr.), up 12%. 9M FY 2025, Sale was Rs. 1,083 cr. (Rs. 982 cr.), up 10%.</p> <p>As per <u>IQVIA MAT December 2024</u>, Ajanta's growth was 11% versus IPM growth of 8%. This higher than IPM growth is contributed mainly by volumes. Therapeutic growths were as below:</p> <ul style="list-style-type: none"> • <u>Cardiology</u>: 11% against segment growth of 12%. • <u>Ophthalmology</u>: 6% against segment growth of 4%. • <u>Dermatology</u>: 16% against segment growth of 10%. • <u>Pain Management</u>: 11% against segment growth of 7%.
Asia	<p>Q3 FY 2025, Sale was Rs. 316 cr. (Rs. 292 cr.), up 8%. 9M FY 2025, Sale was Rs. 888 cr. (Rs. 776 cr.), up 14%.</p>
Africa	<p>Q3 FY 2025, Sale was Rs. 173 cr. (Rs. 155 cr.), up 12%. 9M FY 2025, Sale was Rs. 617 cr. (Rs. 472 cr.), up 31%.</p>
Total Branded Generic	<p>Q3 FY 2025, Sale was Rs. 834 cr. (Rs. 755 cr.), up 10%. 9M FY 2025, Sale was Rs. 2,588 cr. (Rs. 2,230 cr.), up 16%.</p>

US Generic Business:

USA	<p>Q3 FY 2025, Sale was Rs. 263 cr. (Rs. 252 cr.), up 4%. 9M FY 2025, Sale was Rs. 723 cr. (Rs. 703 cr.), up 3%.</p> <p>During 9M, we received 5 ANDA final approval & filed 4 ANDA's.</p> <p>Out of 51 final ANDA approvals, we have commercialized 48.</p> <p>We hold 2 tentative approvals and 21 ANDAs are awaiting US FDA approval.</p>
------------	--

Africa Institution Business:

Africa Institution	<p>Q3 FY 2025, Sale was Rs. 33 cr. (Rs. 86 cr.), down 61%. 9M FY 2025, Sale was Rs. 118 cr. (Rs. 188 cr.), down 37%.</p>
---------------------------	--

R&D:

Q3 FY 2025, R&D expenses were Rs. 53 cr., (Rs. 52 cr.), 5% of revenue.

9M FY 2025, R&D expenses were Rs. 161 cr., (Rs. 157 cr.), 5% of revenue.

Note: Figures in bracket are for corresponding year same period.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa. Company has ground presence in each of these 30+ countries. Many of company's products are 1st to market and are leading in their sub-therapeutic segments. Company also has presence in USA in generic business and institution business in Africa.

Company's state of the art R&D centre is located in Mumbai. Company has 7 world class manufacturing facilities located in India.

For the Last 5 financial years, company has posted healthy revenue CAGR of 13% and even stronger PAT CAGR of 15%.

Earnings Conference Call

The Company will host an Earnings Conference Call at 1630 hrs. IST (1900 hrs. SST/HKT, 1100 hrs. GMT, 0600 hrs. US ET), during which the leadership team will discuss the financial performance and take questions. A transcript of the conference call will be available at www.ajantapharma.com.

Dial-in Information

Date and Time	January 30, 2025 at 1630 – 1730 hrs IST 1900 – 2000 hrs SST/HKT 1100 – 1200 hrs GMT 0600 – 0700 hrs US ET
Dial-in Numbers	
Diamond pass link for faster access	Click here to register
Universal Access	Primary Access: (+91 22 6280 1542) (+91 22 7115 8372)
International Toll Free	USA: 18667462133 UK: 08081011573 Hong Kong: 800964448 Singapore: 8001012045

Process for dial-in are given as below:

1. Register through the Diamond pass link.
2. You will receive a calendar invite along with a passcode and a PIN number. The passcode and PIN will be activated 30 minutes prior to the conference scheduled time.
3. Dial the 'conference Dial-in number' you receive on your email.
4. On system prompt, dial the PASSCODE followed by # key.
5. On system prompt, enter the PIN followed by # key.
6. If the line gets disconnected, you need to dial the 'conference dial-in number' again and follow the above steps.

Playback of Earnings Conference Call audio:

Playback of the earnings call will be available 120 minutes after the end of the call on our website (www.ajantapharma.com).

For more details visit www.ajantapharma.com

For regular updates follow us on x.com – <https://x.com/AjantaPharmaLtd>

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 6060 9706 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 6060 9721 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331

Corporate Identity Number (CIN): L24230M9M979PLC022059

Safe Harbour Statement

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2024

₹ in Crore

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	1,146.13	1,186.64	1,105.15	3,477.69	3,154.63	4,208.71
Other income (Refer note 3)	30.44	19.48	13.59	76.39	49.10	84.60
Total Income	1,176.57	1,206.12	1,118.74	3,554.08	3,203.73	4,293.31
Expenses						
Cost of materials consumed	210.14	207.09	239.05	655.64	680.40	939.43
Purchases of stock-in-trade	78.55	45.79	39.29	169.62	125.91	166.35
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(30.88)	8.80	15.83	(37.92)	(4.12)	(39.21)
Employee benefits expense	265.17	260.96	231.35	809.91	666.83	900.34
Finance costs	7.91	6.02	2.49	14.66	5.68	7.21
Depreciation and amortisation expense	35.97	34.39	34.26	104.33	101.15	135.40
Other expenses (Refer note 3)	302.32	352.83	265.56	918.09	791.99	1,069.86
Total Expenses	869.18	915.88	827.83	2,634.33	2,367.84	3,179.38
Profit before tax	307.39	290.24	290.91	919.75	835.89	1,113.93
Tax Expense						
Current Tax	94.85	76.11	91.31	250.34	248.95	322.06
Deferred Tax	(20.34)	(2.35)	(10.43)	(25.72)	(26.51)	(24.30)
Net Profit for the period	232.88	216.48	210.03	695.13	613.45	816.17
Other Comprehensive Income (OCI)						
Items that will be reclassified subsequently to profit or loss	1.85	7.27	3.32	4.21	8.79	3.33
Income tax relating to items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Items that will not be reclassified subsequently to profit or loss	(0.63)	(2.40)	(0.86)	(6.77)	(2.44)	(3.88)
Income tax relating to items that will not be reclassified to profit or loss	0.22	0.84	0.30	2.37	0.85	1.36
Other Comprehensive Income for the year, net of tax	1.44	5.71	2.76	(0.19)	7.20	0.81
Total Comprehensive Income for the period	234.32	222.19	212.79	694.94	620.65	816.98
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.27	25.07	25.27	25.27
Other Equity						3,542.09
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	18.60	17.27	16.68	55.52	48.72	64.82
(b) Diluted - in ₹	18.59	17.26	16.67	55.49	48.68	64.77

Notes :

1. The above consolidated unaudited financial results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2025. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2024. The review report has been filed with the stock exchange and is available on company website.

2. The consolidated unaudited financial results of the Company and its wholly owned subsidiaries ("the Group") have been prepared as per Ind AS 110 on Consolidated Financial Statements. There is no minority interest.

3. Other income / Other expense includes :

₹ in Crore	Quarter ended			Nine months ended		Year ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
Foreign exchange gain (in other income)	17.59	12.13	4.11	26.21	19.03	38.69
Foreign exchange loss (in other expense)	-	25.65	7.58	13.88	-	-

4. During nine month ended 31 December 2023, 25,325 (previous year 1,000) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by ₹ 50,650 (previous year ₹ 2,000) and securities premium by ₹ 3.84 crores (previous year ₹ 0.18 crores).

5. On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at ₹ 2,770 per equity share for an aggregate amount of ₹ 285.00 crores. The buy back opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024.

6. The Group operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

7. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.

REKHA SHENOY
Digitally signed by
REKHA SHENOY
Date: 2025.01.30
15:11:23 +05'30'

Yogesh Agrawal
Digitally signed
by Yogesh
Agrawal
Date: 2025.01.30
14:51:54 +05'30'

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2025

Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December 2024

₹ in Crore

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Income						
Revenue from operations	1,101.92	1,128.91	1,085.29	3,308.10	3,045.05	3,971.12
Other income (Refer note 2)	33.23	40.34	13.73	101.94	82.80	116.48
Total Income	1,135.15	1,169.25	1,099.02	3,410.04	3,127.85	4,087.60
Expenses						
Cost of materials consumed	210.14	207.09	239.04	655.64	680.40	939.43
Purchases of stock-in-trade	40.23	42.62	37.64	127.46	121.90	162.16
Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.00	17.60	31.01	(3.48)	37.25	(22.17)
Employee benefits expense	245.71	241.65	216.41	753.04	618.19	834.16
Finance costs	2.48	0.73	2.36	3.93	5.38	6.80
Depreciation and amortisation expense	34.93	33.32	33.41	101.17	98.69	132.16
Other expenses (Refer note 2)	265.51	317.04	234.01	820.37	695.03	938.11
Total Expenses	803.00	860.05	793.88	2,458.13	2,256.84	2,990.65
Profit before tax	332.15	309.20	305.14	951.91	871.01	1,096.95
Tax Expense						
Current Tax	76.38	71.13	81.94	218.93	217.75	277.58
Deferred Tax	3.32	3.09	3.05	9.52	8.71	12.13
Net Profit for the period	252.45	234.98	220.15	723.46	644.55	807.24
Other Comprehensive Income (OCI)						
Items that will not be reclassified subsequently to profit or loss	(0.63)	(2.40)	(0.86)	(6.77)	(2.44)	(3.88)
Income tax relating to items that will not be reclassified to profit or loss	0.22	0.84	0.30	2.37	0.85	1.36
Other Comprehensive Income for the year, net of tax	(0.41)	(1.56)	(0.56)	(4.40)	(1.59)	(2.52)
Total Comprehensive Income for the period	252.04	233.42	219.59	719.06	642.96	804.72
Paid-up Equity Share Capital (Face value of ₹ 2 each)	25.07	25.07	25.27	25.07	25.27	25.27
Other Equity						3,388.30
Earnings Per Share (Face value of ₹ 2 each)						
(a) Basic - in ₹	20.16	18.75	17.48	57.79	51.19	64.11
(b) Diluted - in ₹	20.15	18.74	17.47	57.76	51.15	64.06

Notes :

1. The above standalone unaudited results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 30 January 2025. The statutory auditors have expressed unmodified opinion on the results for the quarter and nine month period ended 31 December 2024. The review report has been filed with the stock exchange and is available on company website.

2. Other income / Other expense includes :

₹ in Crore	Quarter ended			Nine months ended		Year ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
Dividend from subsidiaries (in other income)	-	22.28	-	22.28	29.13	29.13
Foreign exchange gain (in other income)	20.72	10.95	3.63	30.73	24.89	43.16
Foreign exchange loss (in other expense)	-	25.65	7.58	13.88	-	-

3. During nine month ended 31 December 2024, 25,325 (previous year 1,000) equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Share Based Incentive Plan, 2019, resulting in an increase in the paid-up share capital by ₹ 50,650 (previous year ₹ 2,000) and securities premium by ₹ 3.84 crores (previous year ₹ 0.18 crores).

4. On 2 May 2024, Company has announced buy back of its 10,28,881 equity shares, being 0.82% of the total paid up equity share capital at ₹ 2,770 per equity share for an aggregate amount of ₹ 285.00 crores. The buy back opened on 05 June 2024, closed on 11 June 2024 and Company extinguished those shares on 27 June 2024.

5. The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".

6. The Financial Results are available for investors on the company's website www.ajantapharma.com and stock exchange websites www.nseindia.com and www.bseindia.com.

By order of the Board
For Ajanta Pharma Ltd.

REKHA SHENOY Digitally signed by
REKHA SHENOY
Date: 2025.01.30
15:07:21 +05'30'

Yogesh Agrawal Digitally signed by
Yogesh Agrawal
Date: 2025.01.30
14:52:11 +05'30'

Yogesh M. Agrawal
Managing Director

Mumbai, 30 January 2025